JMP Securities Reiterates Market Outperform on Athira Pharma, Maintains $19 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities has reiterated its Market Outperform rating on Athira Pharma (NASDAQ:ATHA) and maintained a price target of $19.
May 16, 2024 | 4:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has reiterated its Market Outperform rating on Athira Pharma and maintained a price target of $19. This suggests confidence in the company's future performance and potential for stock price appreciation.
The reiteration of a Market Outperform rating and a maintained price target of $19 by JMP Securities indicates strong confidence in Athira Pharma's future performance. This is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100